top of page
The Professional Network for Healthcare Experts
Sentynl secures option for US alvelestat rights in Phase III-ready AATD lung disease programme
The agreement gives Zydus subsidiary Sentynl Therapeutics an option for exclusive US commercial and global manufacturing rights to Mereo BioPharma’s oral neutrophil elastase inhibitor, with Mereo leading preparations for pivotal development.
nuaxia
Aug 143 min read
Mereo grants Sentynl US option for alvelestat in deal worth up to $475 million
The agreement gives Sentynl an exclusive pathway to commercialise the Phase III-ready rare lung disease therapy in the US while providing global manufacturing rights and funding support for late-stage development.
nuaxia
Aug 133 min read
bottom of page